Skip to content

Biohaven BHVN Investing Cash Flow

Investing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$3.92B-16.8%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$407.28M-1,280%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$37.94M+80.4%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$11.84M-90.7%
uniQure logo
uniQureQURE
$98.56M+390%
Roivant Sciences logo
Roivant SciencesROIV
-$1.09B-112,409%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's investing cash flow?
Biohaven (BHVN) reported investing cash flow of $15.21M in Q1 2026.
How has Biohaven's investing cash flow changed year-over-year?
Biohaven's investing cash flow decreased by 90.8% year-over-year, from $164.88M to $15.21M.
What is the long-term trend for Biohaven's investing cash flow?
Over 3 years (2021 to 2024), Biohaven's investing cash flow has grown at a 537.8% compound annual growth rate (CAGR), from $944K to -$244.97M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.